Nanda Kavita, Stuart Gretchen S, Robinson Jennifer, Gray Andrew L, Tepper Naomi K, Gaffield Mary E
aFHI 360, Durham bUniversity of North Carolina Medical School, Chapel Hill cJohns Hopkins University School of Medicine, Baltimore, Maryland, USA dDivision of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa eDivision of Reproductive Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA fDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
AIDS. 2017 Apr 24;31(7):917-952. doi: 10.1097/QAD.0000000000001392.
To summarize published evidence on drug interactions between hormonal contraceptives and antiretrovirals.
Systematic review of the published literature.
We searched PubMed, POPLINE, and EMBASE for peer-reviewed publications of studies (in any language) from inception to 21 September 2015. We included studies of women using hormonal contraceptives and antiretrovirals concurrently. Outcomes of interest were effectiveness of either therapy, toxicity, or pharmacokinetics. We used standard abstraction forms to summarize and assess strengths and weaknesses.
Fifty reports from 46 studies were included. Most antiretrovirals whether used for therapy or prevention, have limited interactions with hormonal contraceptive methods, with the exception of efavirenz. Although depot medroxyprogesterone acetate is not affected, limited data on implants and combined oral contraceptive pills suggest that efavirenz-containing combination antiretroviral therapy may compromise contraceptive effectiveness of these methods. However, implants remain very effective despite such drug interactions. Antiretroviral plasma concentrations and effectiveness are generally not affected by hormonal contraceptives.
Women taking antiretrovirals, for treatment or prevention, should not be denied access to the full range of hormonal contraceptive options, but should be counseled on the expected rates of unplanned pregnancy associated with all contraceptive methods, in order to make their own informed choices.
总结已发表的关于激素避孕药与抗逆转录病毒药物之间药物相互作用的证据。
对已发表文献进行系统综述。
我们在PubMed、POPLINE和EMBASE中检索了从创刊至2015年9月21日的同行评审研究出版物(不限语言)。我们纳入了同时使用激素避孕药和抗逆转录病毒药物的女性的研究。感兴趣的结果是任何一种治疗的有效性、毒性或药代动力学。我们使用标准的摘要表格来总结和评估优缺点。
纳入了46项研究的50份报告。大多数抗逆转录病毒药物,无论用于治疗还是预防,与激素避孕方法的相互作用有限,但依非韦伦除外。虽然醋酸甲羟孕酮长效注射剂不受影响,但关于皮下埋植剂和复方口服避孕药的有限数据表明,含依非韦伦的抗逆转录病毒联合治疗可能会损害这些方法的避孕效果。然而,尽管存在此类药物相互作用,皮下埋植剂仍然非常有效。抗逆转录病毒药物的血浆浓度和有效性通常不受激素避孕药的影响。
接受抗逆转录病毒药物治疗或预防的女性不应被剥夺使用所有激素避孕方法的权利,但应就所有避孕方法相关的意外怀孕预期发生率提供咨询,以便她们做出明智的选择。